Ventyx Biosciences Newsroom

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Latest 15% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures

Yahoo FinanceNov 17 21:07

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 12 20:30

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

TipRanksNov 12 12:01

Ventyx Biosciences Analyst Ratings

BenzingaNov 9 00:28 · Ratings

LifeSci Capital Maintains Ventyx Biosciences(VTYX.US) With Buy Rating

Futu NewsNov 8 22:31 · Ratings

Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $9

Futu NewsNov 8 22:31 · Ratings

Ventyx Biosciences (VTYX) Receives a Buy From LifeSci Capital

TipRanksNov 8 21:46 · Ratings

Express News | Ventyx Biosciences : Oppenheimer Cuts Target Price to $9 From $10

BreakingsNov 8 21:08

Ventyx Biosciences Files Offering of Common Stock

Seeking AlphaNov 8 06:45

Express News | Ventyx Biosciences Inc: Cash Balance of $274.8M as of September 30, 2024 Expected to Fund Operations Into at Least H2 2026

BreakingsNov 8 06:07

Ventyx Biosciences | 10-Q: Q3 2024 Earnings Report

SECNov 8 06:04 · Announcements

Earnings Flash (VTYX) VENTYX BIOSCIENCES Reports Q3 Loss $-0.50

MT NewswiresNov 8 05:31

Express News | Ventyx Biosciences Q3 Net Income USD -35.249 Million

BreakingsNov 8 05:05

Press Release: Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Dow JonesNov 8 05:05

Watching Regulus Therapeutics; Shares See Volume To The Upside As Traders Circulate TipRanks Article Titled 'These 2 'Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts'

BenzingaOct 28 23:22

H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6

Futu NewsOct 16 00:31 · Ratings

Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold

TipRanksOct 15 23:45 · Ratings

Express News | Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of Vtx002 (Tamuzimod) in Ulcerative Colitis at Ueg Week 2024

BreakingsOct 15 20:00

Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

GlobeNewswireOct 15 20:00

Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Maintains Target Price $10

Oppenheimer analyst Jeff Jones maintains $Ventyx Biosciences(VTYX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 37.9%

Futu NewsSep 24 20:31 · Ratings